Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neuroprotective drug for cerebral arterial thrombosis

A technology for ischemic stroke and neuroprotection, applied in drug combinations, neurological diseases, pharmaceutical formulations, etc., to reduce or stabilize the disease, reduce ischemic infarct size, and improve behavior.

Active Publication Date: 2021-04-13
SICHUAN UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no reports on tFNAs related research in ischemic stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neuroprotective drug for cerebral arterial thrombosis
  • Neuroprotective drug for cerebral arterial thrombosis
  • Neuroprotective drug for cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Synthesis of Example 1 tFNAs

[0033] 1. Synthesis method

[0034] Dissolve the four DNA single strands (S1, S2, S3, S4) in TM Buffer (10mM Tris-HCl, 50mM MgCl 2 , pH=8.0), so that the final concentration of the four DNA single strands is 1000nM, mix well, heat quickly to 95°C and keep it for 10 minutes, then quickly cool down to 4°C and keep it for more than 20 minutes, you can get tetrahedral skeleton nucleic acid TFNAS.

[0035] The sequences of the four single strands (5'→3') are as follows:

[0036] S1:

[0037]

[0038] S2:

[0039]

[0040] S3:

[0041]

[0042] S4:

[0043]

[0044] 2. Identification

[0045] From the results of PAGE gel, it can be seen that the size of TFNAS is about 200bp ( figure 1 ); Scattered point-like objects can be seen by transmission electron microscopy, and some point-like objects can be observed to present a tetrahedral shape ( figure 2 ).

[0046] From the aforementioned identification results, it can be consi...

experiment example 1

[0048] Experimental example 1 Neuroprotective effect of tFNAs

[0049] 1. Method

[0050] (1) Animal treatment in groups

[0051] SD male rats weighing 210-230 g were divided into 3 groups.

[0052] a. Sham operation group (sham): the right common carotid artery of rats was permanently ligated.

[0053] b. Normal saline group (saline, SA): Permanent ligation of the right common carotid artery and external carotid artery of rats, using a 0.4mm diameter silicone head thread plug to insert the internal carotid artery from the bifurcation of the common carotid artery, and plug it into the back of the cranium Middle cerebral artery for 1 hour. When the middle cerebral artery was blocked, 200 microliters of normal saline was injected into the tail vein at the same time. After 1 hour, the thread plug was removed.

[0054] c. Experimental group (tFNAs): The right common carotid artery and external carotid artery of rats were ligated for a long time, and a 0.4mm diameter silicone ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a neuroprotective drug for cerebral arterial thrombosis, and belongs to the field of biotechnology drugs. The drug is prepared by taking a DNA tetrahedron as an active component and adding pharmaceutically acceptable auxiliary components. The drug disclosed by the invention can be used for effectively protecting cranial nerves and greatly reducing the infarction area caused by cerebral arterial thrombosis, and can be used for improving the behavioral capacity of patients with relatively light illness conditions; and for patients with relatively severe illness, the illness can be stabilized, and the treatment window period is prolonged.

Description

technical field [0001] The invention belongs to the field of biotechnology medicine. Background technique [0002] A stroke, commonly known as a stroke, is damage to brain tissue caused by damage to blood vessels in the brain. Stroke is the most common cause of disability and a common cause of death in developed countries. In my country, stroke is the leading cause of death and disability in adults, and has the characteristics of high incidence, disability, mortality and recurrence. Stroke is generally divided into two categories, namely ischemic stroke and hemorrhagic stroke. Among them, ischemic stroke is the most common clinically, accounting for about 70% of stroke in my country. [0003] After the occurrence of ischemic stroke, the nerve cells in the infarct center area can undergo necrosis and apoptosis within a few minutes, while the ischemic penumbra around the infarction center area will lead to neurological function silence due to the decrease of blood flow. Am...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/711A61P25/00A61P9/10
CPCA61K31/711A61P25/00A61P9/10
Inventor 林云锋周蜜张天旭蔡潇潇
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com